keyword
MENU ▼
Read by QxMD icon Read
search

Letrozol

keyword
https://www.readbyqxmd.com/read/28630466/comparative-effectiveness-of-9-ovulation-induction-therapies-in-patients-with-clomiphene-citrate-resistant-polycystic-ovary-syndrome-a-network-meta-analysis
#1
Yiping Yu, Lanlan Fang, Ruizhe Zhang, Jingyan He, Yujing Xiong, Xiaoyi Guo, Qingyun Du, Yan Huang, Yingpu Sun
The comparative efficacies of ovulation-induction treatments in patients with clomiphene citrate-resistant (CCR) polycystic ovary syndrome (PCOS) are not well known. Therefore, we conducted a network meta-analysis to rank the reproductive efficacies of these treatments. We ultimately included 26 randomized clinical trials with 2722 participants and 9 types of therapies: clomiphene citrate (CC), metformin, letrozole, follicle stimulating hormone (FSH), human menopausal gonadotropin (hMG), unilateral laparoscopic ovarian drilling (ULOD), bilateral laparoscopic ovarian drilling (BLOD), the combination of metformin with letrozole (metformin+letrozole), and the combination of metformin with CC (metformin+CC)...
June 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28629583/ex%C3%A2-vivo-retrieval-and-cryopreservation-of-oocytes-from-oophorectomized-specimens-for-fertility-preservation-in-a-brca1-mutation-carrier-with-ovarian-cancer
#2
Nigel Pereira, Andrea G Hubschmann, Jovana P Lekovich, Glenn L Schattman, Zev Rosenwaks
OBJECTIVE: To report a case of ex vivo oocyte retrieval from oophorectomized specimens in a BRCA1 mutation carrier undergoing surgical staging for ovarian cancer. DESIGN: Video case report and literature review. SETTING: University-affiliated center. PATIENT(S): A 37-year-old single woman, gravida 0, with a known BRCA1 mutation, presented to her oncologist with a complex right ovarian mass and elevated CA-125 level...
June 16, 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/28619389/the-promising-effect-of-linagliptin-and-or-indole-3-carbinol-on-experimentally-induced-polycystic-ovarian-syndrome-the-role-of-transforming-growth-factor-beta-1-oxidative-stress-and-nrf2-ho-1-pathway
#3
Ahmed M Kabel, Aisha H Al-Shehri, Rehab A Altalhi
Polycystic ovarian syndrome (PCOS) is one of the most common medical condition that leads to female infertility worldwide. The aim of this study was to assess the effect of linagliptin and/or indole-3-carbinol (I3C) on PCOS in female rats. Fifty female Wistar rats were randomly allocated into five equal groups: Control group; Letrozole induced PCOS group; Letrozole + Linagliptin group; Letrozole + I3C group and Letrozole + Linagliptin + I3C group. Body weight, body mass index, Lee index and ovarian indices were determined...
June 12, 2017: Chemico-biological Interactions
https://www.readbyqxmd.com/read/28614542/use-of-anastrozole-in-the-chemoprevention-and-treatment-of-breast-cancer-a-literature-review
#4
Maria da Conceição Barros-Oliveira, Danylo Rafhael Costa-Silva, Danielle Benigno de Andrade, Umbelina Soares Borges, Cléciton Braga Tavares, Rafael Soares Borges, Janaína de Moraes Silva, Benedito Borges da Silva
Aromatase inhibitors have emerged as an alternative endocrine therapy for the treatment of hormone sensitive breast cancer in postmenopausal women. The use of third-generation inhibitors represented by exemestane, letrozol and anastrozole is currently indicated. Anastrozole is a nonsteroidal compound and a potent selective inhibitor of the aromatase enzyme. Although a few studies have shown that its pharmacodynamic and pharmacokinetic properties may be affected by interindividual variability, this drug has been recently used in all configurations of breast cancer treatment...
April 2017: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/28598116/-optimal-ovulation-induction-in-polycystic-ovary-syndrome-resistant-to-clomiphene-citrate-or-letrozole
#5
Ying Chen, Dan Zhang
OBJECTIVES: To investigate the optimal ovulation induction with the combination of combining letrozole(LE),clomiphene citrate (CC),and human menopausal gonadotropin (HMG) in polycystic ovary syndrome(PCOS) patients resistant to CC or LE. METHODS: Two hundreds nine PCOS patients (209 cycles) resistant to CC or LE were randomly divided into three groups: CC+HMG group (59 cycles),LE+HMG group (72 cycles) and LE+CC group (78 cycles).The patients in LE+CC group unable to form the dominant follicle after 54 cycles were enrolled into LE+CC+HMG group...
November 2016: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/28585619/-palbociclib-combinations-as-new-therapeutic-strategies-in-the-treatment-of-hr-her2-advanced-breast-cancer
#6
Katalin Boér
Until recently, the only endocrine agents used to treat HR+/HER2- advanced breast cancers were tamoxifen, aromatase inhibitors and fulvestrant, although a substantial proportion of patients relapse on these standard therapies. Intensive research has been conducted to develop new strategies to overcome endocrine resistance and to enhance the efficacy of endocrine treatments by combining hormone therapy with other targeted treatment approaches. The development of selective CDK4/6 inhibitors and the introduction of palbociclib, the first molecule in this class in clinical practice, represent an important step in the treatment of HR+ advanced breast cancer...
June 6, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28580881/blocking-the-cycle-cyclin-dependent-kinase-4-6-inhibitors-in-metastatic-hormone-receptor-positive-breast-cancer
#7
Seth A Wander, Erica L Mayer, Harold J Burstein
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
June 3, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28578791/letrozole-an-aromatase-inhibitor-reduces-post-peak-age-related-regression-of-rooster-reproductive-performance
#8
Emad Abdulgabbar Ali, Mahdi Zhandi, Armin Towhidi, Mojtaba Zaghari, Mahdi Ansari, Mojtaba Najafi, Hamid Deldar
This study was designed to evaluate orally administrated Letrozole (Lz) on reproductive performance, plasma testosterone and estradiol concentrations and relative abundance of mRNA of GnRH, FSH and LH in roosters. Ross 308 roosters (n=32) that were 40-weeks of age were individually housed and received a basal standard diet supplemented different amounts of capsulated Lz [0 (Lz-0), 0.5 (Lz-0.5), 1 (Lz-1) or 1.5 (Lz-1.5), mg Lz/bird/day] for 12 weeks. Sperm quality variables and plasma testosterone and estradiol concentrations were assessed from the first to the tenth week of the treatment period...
May 27, 2017: Animal Reproduction Science
https://www.readbyqxmd.com/read/28570161/a-phase-ii-clinical-trial-of-an-aromatase-inhibitor-for-postmenopausal-women-with-lymphangioleiomyomatosis
#9
Calvin Lu, Hye-Seung Lee, George P Pappas, Daniel F Dilling, Charles D Burger, Adrian Shifren, Srihari Veeraraghavan, Jeffrey T Chapman, Joseph Parambil, Stephen J Ruoss, Lisa R Young, Stephen R Hammes, Elizabeth J Kopras, Tammy Roads, Jeffrey P Krischer, Francis X McCormack
RATIONALE: Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease that predominantly affects women and can worsen with pregnancy, estrogen treatment, and the menstrual cycle, suggesting an important role for estrogen in disease pathogenesis. OBJECTIVES: To assess the efficacy and safety of the aromatase inhibitor letrozole in the treatment of LAM. METHODS: Seventeen postmenopausal women with LAM were enrolled in this phase II trial and randomized to receive letrozole 2...
June 2017: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/28562472/gonadotropin-releasing-hormone-agonist-combined-with-a-levonorgestrel-releasing-intrauterine-system-or-letrozole-for-fertility-preserving-treatment-of-endometrial-carcinoma-and-complex-atypical-hyperplasia-in-young-women
#10
Huimei Zhou, Dongyan Cao, Jiaxin Yang, Keng Shen, Jinghe Lang
OBJECTIVES: The aim of this study was to evaluate the efficacy and safety with gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine system or an aromatase inhibitor (letrozole) in young women with well-differentiated early endometrial carcinoma (EC) and complex atypical hyperplasia (CAH). METHODS: We performed a retrospective analysis including the clinical characteristics of 29 patients younger than 45 years with early well-differentiated endometrioid adenocarcinoma of the uterus (EC) or CAH who were treated at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, from January 2012 to April 2016...
May 29, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28560011/peutz-jeghers-syndrome-with-early-onset-of-pre-adolescent-gynecomastia-a-predigree-case-report-and-clinical-and-molecular-genetic-analysis
#11
Long-Jiang Zhang, Zhe Su, Xia Liu, Li Wang, Qin Zhang
This study reports a case of Peutz-Jeghers syndrome with early onset of gynecomastia, and discusses its clinical characteristics and genetic changes in a family. The clinical characteristics of a child diagnosed with Peutz-Jeghers syndrome in our hospital and his parents were summarized, and related genes were detected in the child and his parents. Furthermore, the therapeutic effect of letrozole was also observed. A five-year-and-three-month-old male patient visited a doctor due to "progressive painless enlargements at bilateral breast for more than two years"...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28557652/comparison-of-clomiphene-citrate-and-letrozole-for-ovulation-induction-in-women-with-polycystic-ovary-syndrome-a-prospective-randomized-trial
#12
Chang Liu, Guimei Feng, Wei Huang, Qiuyi Wang, Shiyuan Yang, Jing Tan, Jing Fu, Dong Liu
To compare the therapeutic efficacy of clomiphene citrate (CC) and letrozole (LE) on ovulation, pregnancy, and live birth in women with polycystic ovary syndrome (PCOS); and to ensure if LE can replace CC as the first-line therapy for ovulation induction in these women. This is a prospectively, randomized, controlled trial in the tertiary hospital. Two-hundred and sixty-eight anovulatory PCOS patients were treated by CC or CC plus metformin and LE or LE plus metformin for three continuous cycles or conception; their ovulation rates, pregnancy rates, and live birth rates were calculated and compared...
May 30, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28538887/ductal-eccrine-carcinoma-of-the-axilla-a-diagnostic-pitfall
#13
Maria Helena Toda Sanches de Brito, Cecília Silva Nunes de Moura Dionísio, Joana Cintia Monteiro Ferreira, Maria Joaninha Madalena de Palma Mendonça da Costa Rosa, Fernando Petrucci Bernardo E Cunha, Maria Manuela Antunes Pecegueiro da Silva Garcia
Ductal eccrine carcinoma (DEC) is a rare sweat gland carcinoma with ductular differentiation. Clinically, it is characterized by a slowly growing, hardened plaque or nodule predominantly located on the head and neck. Histologically, DEC shares similar features to invasive breast carcinoma, thus causing great diagnostic challenges. We report a 69-year-old woman who presented with a hardened plaque on the axilla. A skin biopsy was performed and metastatic invasive breast carcinoma could not be ruled out. Complete excision and further workup were subsequently conducted, leading to the diagnosis of estrogen receptor positive DEC with associated axillary lymph node metastases...
March 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28530853/designing-clinical-trials-that-accept-new-arms-an-example-in-metastatic-breast-cancer
#14
Steffen Ventz, Brian M Alexander, Giovanni Parmigiani, Richard D Gelber, Lorenzo Trippa
Purpose The majority of randomized oncology trials are two-arm studies that test the efficacy of new therapies against a standard of care, thereby assigning a large proportion of patients to nonexperimental therapies. In contrast, multiarm studies efficiently share a common control arm while evaluating multiple experimental therapies. A major bottleneck for traditional multiarm trials is the requirement that all therapies-often drugs from different companies-have to be available at the same time when the trial starts...
May 22, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28496306/erratum-combined-letrozole-and-clomiphene-versus-letrozole-and-clomiphene-alone-in-infertile-patients-with-polycystic-ovary-syndrome-erratum
#15
(no author information available yet)
[This corrects the article on p. 1427 in vol. 7.][This corrects the article on p. 1427 in vol. 7.].
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28488912/a-high-level-of-estrogen-stimulated-proteins-selects-breast-cancer-patients-treated-with-adjuvant-endocrine-therapy-with-good-prognosis
#16
Katrine L H Weischenfeldt, Tove Kirkegaard, Birgitte B Rasmussen, Anita Giobbie-Hurder, Maj-Britt Jensen, Bent Ejlertsen, Anne E Lykkesfeldt
BACKGROUND: Adjuvant endocrine therapy has significantly improved survival of estrogen receptor α (ER)-positive breast cancer patients, but around 20% relapse within 10 years. High expression of ER-stimulated proteins like progesterone receptor (PR), Bcl-2 and insulin-like growth factor receptor I (IGF-IR) is a marker for estrogen-driven cell growth. Therefore, patients with high tumor levels of these proteins may have particularly good prognosis following adjuvant endocrine therapy...
May 10, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28488183/palbociclib-a-review-in-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer
#17
REVIEW
Esther S Kim, Lesley J Scott
Oral palbociclib (Ibrance®) is a first-in-class, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (i.e. a CDK4/6 inhibitor). It is indicated for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, and in combination with fulvestrant (with or without a luteinizing hormone-releasing hormone agonist) in those previously treated with endocrine therapy. In clinical trials, palbociclib in combination with letrozole as initial endocrine-based therapy in postmenopausal women (PALOMA-1 and PALOMA-2), or in combination with fulvestrant in pre-, peri-, or postmenopausal women with disease progression after endocrine therapy (PALOMA-3), significantly prolonged progression-free survival (PFS) and improved clinical benefit response (CBR) rates...
May 9, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28487215/micturition-dysfunction-in-four-month-old-ovariectomized-rats-effects-of-testosterone-replacement
#18
Sandra M Bonilla-Becerra, Mariana G de Oliveira, Fabiano B Calmasini, Julio A Rojas-Moscoso, Angelina Zanesco, Edson Antunes
AIMS: Androgen deficiency has been implicated in urological complications of postmenopausal women. This study examined the effects of testosterone replacements on the lower urinary tract dysfunction in 4-month old ovariectomized (OVX) rats. MAIN METHODS: Sprague-Dawley female rats were OVX bilaterally. Three months later, rats received single intramuscular injections of testosterone undecanoate. Cystometric study, and bladder and urethra smooth muscle reactivities were evaluated...
May 6, 2017: Life Sciences
https://www.readbyqxmd.com/read/28472324/cost-effectiveness-of-palbociclib-in-hormone-receptor-positive-advanced-breast-cancer
#19
H Mamiya, R K Tahara, S M Tolaney, N Choudhry, M Najafzadeh
BACKGROUND: Palbociclib, a novel small-molecule inhibitor of cyclin-dependent kinases 4 and 6 for the treatment of advanced breast cancer, has demonstrated significant efficacy in prolonging progression-free survival when added to existing therapies. Considering the high cost of palbociclib, we assessed cost-effectiveness of adding palbociclib to usual care in treatment of advanced breast cancer. METHODS: We developed a discrete event simulation model to simulate time to cancer progression and to compare life time clinical benefit and cost of alternative treatment strategies for patients with metastatic disease from societal perspective...
May 2, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28463012/comparison-of-palbociclib-in-combination-with-letrozole-or-fulvestrant-with-endocrine-therapies-for-advanced-metastatic-breast-cancer-network-meta-analysis
#20
Costel Chirila, Debanjali Mitra, Ann Colosia, Caroline Ling, Dawn Odom, Shrividya Iyer, James A Kaye
BACKGROUND: Palbociclib is the first cyclin-dependent kinase 4/6 inhibitor approved in the United States for HR+/HER2- advanced/metastatic breast cancer, in combination with letrozole as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression following endocrine therapy. We compared progression-free survival (PFS) and discontinuations due to adverse events for palbociclib combinations against other endocrine therapies using a mixed-treatment comparison meta-analysis of randomized, controlled trials...
May 16, 2017: Current Medical Research and Opinion
keyword
keyword
48622
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"